Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.49 |
| ▸ | GAA | P10253 | 5/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27943531 | 1.00 | KMT2A (0.55) | KMT2ALMNAMEN1NPSR1ALDH1A1 | |
| SCHEMBL4100479 | 0.98 | KMT2A (0.52) | KMT2ALMNAMEN1NPSR1ALDH1A1 | |
| SCHEMBL3070506 | 0.79 | KDM4E (0.44) | KMT2ALMNAMEN1NPSR1ALDH1A1 | |
| SCHEMBL3070503 | 0.79 | KDM4E (0.44) | KMT2ALMNAMEN1NPSR1ALDH1A1 | |
| SCHEMBL3776494 | 0.78 | MEN1 (0.41) | KMT2ALMNAMEN1NPSR1ALDH1A1 | |
| SCHEMBL27480008 | 0.77 | KMT2A (0.46) | KMT2ALMNAMEN1NPSR1ALDH1A1 | |
| SCHEMBL9356896 | 0.77 | KDM4E (0.52) | KMT2AMEN1ALDH1A1GAARAB9A | |
| Hydrochloric Acid SCHEMBL8434379 | 0.76 | KMT2A (0.44) | KMT2ALMNAMEN1NPSR1ALDH1A1 | |
| SCHEMBL9356593 | 0.74 | KDM4E (0.48) | KMT2AMEN1ALDH1A1RAB9AMAPT | |
| SCHEMBL9130522 | 0.72 | KDM4E (0.39) | KMT2ALMNAMEN1NPSR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3006496-B1 | TIRE RUBBER COMPOSITION AND MANUFACTURING METHOD THEREFOR | BRIDGESTONE CORP (JP) | 2017-07-19 | — | — | EP | claimed |
| EP-3006496-B1 | TIRE RUBBER COMPOSITION AND MANUFACTURING METHOD THEREFOR | BRIDGESTONE CORP (JP) | 2017-07-19 | — | — | EP | disclosed |
| US-20160115296-A1 | TIRE RUBBER COMPOSITION AND MANUFACTURING METHOD THEREFOR | BRIDGESTONE CORPORATION (JP) | 2016-04-28 | — | — | US | disclosed |
| EP-3006496-A1 | TIRE RUBBER COMPOSITION AND MANUFACTURING METHOD THEREFOR | Bridgestone Corporation (JP) | 2016-04-13 | — | — | EP | disclosed |
| EP-2258365-B1 | USE OF ORGANIC COMPOUNDS FOR IMMUNOPOTENTIATION | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2013-05-29 | — | — | EP | disclosed |
| US-8318782-B2 | Mitotic kinesin inhibitor | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-11-27 | — | — | US | disclosed |
| US-20110275827-A1 | Mitotic Kinesin Inhibitor | FUJIFILM CORPORATION (JP) | 2011-11-10 | — | — | US | disclosed |
| EP-1454903-B9 | Thiadiazoline derivatives for treating cancer | KYOWA HAKKO KIRIN CO LTD (JP) | 2011-10-05 | — | — | EP | disclosed |
| EP-2327702-A1 | Mitotic kinesin inhibitor | Kyowa Hakko Kirin Co., Ltd. (JP) | 2011-06-01 | — | — | EP | disclosed |
| US-7902234-B2 | Thiadiazoline derivative | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-03-08 | — | — | US | disclosed |
| US-7759371-B2 | Thiadiazoline derivative | Kyowa Hakko Kinn Co., Ltd. (JP) | 2010-07-20 | — | — | US | disclosed |
| US-7425636-B2 | Thiadiazoline derivative | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2008-09-16 | — | — | US | disclosed |
| US-20080207706-A1 | THIADIAZOLINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD (JP) | 2008-08-28 | — | — | US | disclosed |
| EP-1847534-A2 | Thiadiazoline derivative | Kyowa Hakko Kogyo Co., Ltd (JP) | 2007-10-24 | — | — | EP | disclosed |
| US-20070213380-A1 | Thiadiazoline derivative | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-09-13 | — | — | US | disclosed |
| US-20070155804-A1 | Mitotic kinesin inhibitor | KYOWA HAKKO KOGYO CO., LTD. OF TOKYO, JAPAN FUJI PHOTO FILM CO., LTD. KANAGAWA, JAPAN | 2007-07-05 | — | — | US | disclosed |
| US-20060074113-A1 | Thiadiazoline derivative | KYOWA KIRIN CO., LTD. (JP) | 2006-04-06 | — | — | US | disclosed |
| EP-1616866-A1 | M-STAGE KINESIN INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-01-18 | — | — | EP | disclosed |
| EP-1454903-A1 | THIADIAZOLINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-09-08 | — | — | EP | disclosed |
| US-4035244-A | Electric recording process | MITA INDUSTRIAL COMPANY LIMITED (JA) | 1977-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074113-A1 | Thiadiazoline derivative | BRWD1, RB1, ARG2 | KMT2A 558/4885LMNA 3970/4885MEN1 2153/4885 |
| US-20070155804-A1 | Mitotic kinesin inhibitor | KIF15, KIF5A, KIF5B | KMT2A 514/4885LMNA 3410/4885MEN1 3155/4885 |
| US-20070213380-A1 | Thiadiazoline derivative | BRWD1, RB1, ARG2 | KMT2A 558/4885LMNA 3970/4885MEN1 2153/4885 |
| US-20080207706-A1 | THIADIAZOLINE DERIVATIVE | BRWD1, RB1, ARG2 | KMT2A 558/4885LMNA 3970/4885MEN1 2153/4885 |
| US-20110275827-A1 | Mitotic Kinesin Inhibitor | KIF15, KIF5A, KIF5B | KMT2A 514/4885LMNA 3410/4885MEN1 3155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.